181 related articles for article (PubMed ID: 27379542)
1. Altered matrix metalloproteinase 9 and tissue inhibitor of metalloproteinases 1 levels in children with primary hypertension.
Niemirska A; Litwin M; Trojanek J; Gackowska L; Kubiszewska I; Wierzbicka A; Kułaga Z; Michałkiewicz J
J Hypertens; 2016 Sep; 34(9):1815-22. PubMed ID: 27379542
[TBL] [Abstract][Full Text] [Related]
2. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
[TBL] [Abstract][Full Text] [Related]
3. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents.
Głowińska-Olszewska B; Urban M
Metabolism; 2007 Jun; 56(6):799-805. PubMed ID: 17512313
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy.
Li-Saw-Hee FL; Edmunds E; Blann AD; Beevers DG; Lip GY
Int J Cardiol; 2000 Aug; 75(1):43-7. PubMed ID: 11054505
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
[TBL] [Abstract][Full Text] [Related]
7. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.
Tayebjee MH; Karalis I; Nadar SK; Beevers DG; MacFadyen RJ; Lip GY
Am J Hypertens; 2005 Mar; 18(3):325-9. PubMed ID: 15797648
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
Derosa G; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Tinelli C; Cicero AF
Endothelium; 2006; 13(3):227-31. PubMed ID: 16840178
[TBL] [Abstract][Full Text] [Related]
9. Leukocyte matrix metalloproteinase and tissue inhibitor gene expression patterns in children with primary hypertension.
Trojanek JB; Niemirska A; Grzywa R; Wierzbicka A; Obrycki Ł; Kułaga Z; Szalecki M; Michałkiewicz J; Litwin M
J Hum Hypertens; 2020 May; 34(5):355-363. PubMed ID: 30926902
[TBL] [Abstract][Full Text] [Related]
10. Abnormalities of the extracellular degradation of collagen type I in essential hypertension.
Laviades C; Varo N; Fernández J; Mayor G; Gil MJ; Monreal I; Díez J
Circulation; 1998 Aug; 98(6):535-40. PubMed ID: 9714110
[TBL] [Abstract][Full Text] [Related]
11. Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study.
Hansson J; Lind L; Hulthe J; Sundström J
Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):297-303. PubMed ID: 19387352
[TBL] [Abstract][Full Text] [Related]
12. The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome.
Erman H; Gelisgen R; Cengiz M; Tabak O; Erdenen F; Uzun H
Eur Rev Med Pharmacol Sci; 2016; 20(6):1015-22. PubMed ID: 27049251
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of systemic levels of neutrophilic enzymes in patients with hypertension and chronic periodontitis.
Türkoğlu O; Barış N; Tervahartiala T; Şenarslan Ö; Sorsa T; Atilla G
J Periodontol; 2014 Jul; 85(7):908-16. PubMed ID: 24224962
[TBL] [Abstract][Full Text] [Related]
14. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
Florys B; Głowińska B; Urban M; Peczyńska J
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
[TBL] [Abstract][Full Text] [Related]
15. Role of MMP-2 and MMP-9 in resistance to drug therapy in patients with resistant hypertension.
Lacerda L; Faria AP; Fontana V; Moreno H; Sandrim V
Arq Bras Cardiol; 2015 Aug; 105(2):168-75. PubMed ID: 26039662
[TBL] [Abstract][Full Text] [Related]
16. Crosstalk between obesity and MMP-9 in cardiac remodelling -a cross-sectional study in apparent treatment-resistant hypertension.
Ritter AM; de Faria AP; Barbaro N; Sabbatini AR; Corrêa NB; Brunelli V; Amorim R; Modolo R; Moreno H
Blood Press; 2017 Apr; 26(2):122-129. PubMed ID: 27825280
[TBL] [Abstract][Full Text] [Related]
17. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension Relationship to tissue Doppler indices of diastolic relaxation.
Tayebjee MH; Nadar SK; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):770-4. PubMed ID: 15363818
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in blood as markers for early atherosclerosis in subjects with chronic periodontitis.
Söder PO; Meurman JH; Jogestrand T; Nowak J; Söder B
J Periodontal Res; 2009 Aug; 44(4):452-8. PubMed ID: 18973519
[TBL] [Abstract][Full Text] [Related]
19. [Serum and urinary concentration of selected metalloproteinases and their tissue inhibitors in children with vesicoureteral reflux].
Taranta-Janusz K; Zoch-Zwierz W; Wasilewska A; Tenderenda E; Korzeniecka-Kozerska A
Pol Merkur Lekarski; 2010 Aug; 29(170):88-92. PubMed ID: 20842819
[TBL] [Abstract][Full Text] [Related]
20. MMP-9 Levels and IMT of Carotid Arteries are Elevated in Obese Children and Adolescents Compared to Non-Obese.
Andrade C; Bosco A; Sandrim V; Silva F
Arq Bras Cardiol; 2017 Mar; 108(3):198-203. PubMed ID: 28443954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
